Lipocine (LPCN) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $7.00 | Jan 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $8.00 | Nov 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Aug 20, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Jun 27, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Jun 10, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $8.00 | May 29, 2025 |
| Alliance Global Partners | Initiated Coverage | Buy | $10.00 | Sep 24, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $33.00 | Jul 27, 2023 |
Frequently asked questions
Is LPCN a buy, sell, or hold?
Analysts covering Lipocine currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on LPCN?
On Apr 6, 2026, HC Wainwright & Co. downgraded Lipocine to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.